DBV Technologies to Report First Quarter 2022 Financial Results and Recent Business Developments
DBV Technologies announced a conference call for May 2, 2022, at 5:00 p.m. ET to discuss its first quarter 2022 financial results and corporate updates. The call will be available via teleconference and live webcast. DBV is focused on developing Viaskin™, a platform for epicutaneous immunotherapy aimed at treating food allergies, with ongoing trials for Viaskin Peanut. The company's shares are traded on Euronext and Nasdaq under the symbols DBV and DBVT, respectively.
- Ongoing clinical trials of Viaskin Peanut, showing potential market interest.
- Focus on innovative treatment methods for food allergies, potentially expanding treatment options.
- No specific financial results or guidance provided in the PR, leaving investors uncertain.
Montrouge, France, April 25, 2022
DBV Technologies to Report First Quarter 2022 Financial Results and Recent Business Developments
DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that the Company will host a conference call and live audio webcast on Thursday, May 2, 2022, at 5:00 p.m. ET to report first quarter 2022 financial results and provide a corporate update.
This call is accessible via the below teleconferencing numbers, followed by the reference ID: 89119188.
- United States: 866 374 5140
- Canada: 866 455 3403
- United Kingdom: 808 238 9813
- France: 805 102 712
A live webcast of the call will be available on the Investors & Media section of the Company’s website: https://www.dbv-technologies.com/investor-relations/. A replay of the presentation will also be available on DBV’s website after the event.
About DBV Technologies
DBV Technologies is developing Viaskin™, an investigational proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT™, DBV’s method of delivering biologically active compounds to the immune system through intact skin. With this new class of non-invasive product candidates, the Company is dedicated to safely transforming the care of food allergic patients. DBV’s food allergies programs include ongoing clinical trials of Viaskin Peanut. DBV Technologies has global headquarters in Montrouge, France and North American operations in Basking Ridge, New Jersey. The Company’s ordinary shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345), and the Company’s ADSs (each representing one-half of one ordinary share) are traded on the Nasdaq Global Select Market (Ticker: DBVT).
Investor Contact
Anne Pollak
DBV Technologies
+1 857-529-2363
anne.pollak@dbv-technologies.com
Media Contact
Angela Marcucci
DBV Technologies
+1 646-842-2393
angela.marcucci@dbv-technologies.com
Attachment
FAQ
When will DBV Technologies report its first quarter 2022 financial results?
What is the focus of DBV Technologies?
What is the ticker symbol for DBV Technologies on Nasdaq?
How can I access the live webcast of DBV Technologies' financial results?
